{"id":86160,"date":"2022-01-13T08:50:44","date_gmt":"2022-01-13T08:50:44","guid":{"rendered":"https:\/\/www.commercialriskonline.com\/?p=86160"},"modified":"2022-01-13T08:51:03","modified_gmt":"2022-01-13T08:51:03","slug":"europes-pharma-firms-demand-stronger-ip-protection","status":"publish","type":"post","link":"https:\/\/www.commercialriskonline.com\/europes-pharma-firms-demand-stronger-ip-protection\/","title":{"rendered":"Europe\u2019s pharma firms demand stronger IP protection"},"content":{"rendered":"<div class=\"mp_wrapper\">\n  <div class=\"mepr-unauthorized-excerpt\">\n    <p>The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called upon the EU to significantly strengthen provisions in free-trade agreements (FTAs) to strengthen intellectual property (IP) protection f...<\/p>\n  <\/div>\n  <div class=\"mepr-unauthorized-message\">\n    <hr \/>\n<h2 style=\"text-align: center\">Want to read this article?<\/h2>\n<p><a href=\"https:\/\/www.commercialriskonline.com\/subscribe\/\">Register<\/a> for ultimate access to this article and ALL our premium content<\/p>\n<p><strong>ULTIMATE ACCESS<\/strong><strong> PROVIDES YOU WITH<\/strong><\/p>\n<ul>\n<li>Unrestricted access to Commercial Risk, Commercial Risk Europe and Global Risk Manager news, exclusive expert analysis and opinion<\/li>\n<li>Breaking news, daily and\/or weekly Commercial Risk Europe newsletters and regular digital publications<\/li>\n<li>Breaking news, weekly and monthly Global Risk Manager newsletters and quarterly digital Journal<\/li>\n<li>European and global surveys, rankings and special reports<\/li>\n<li>National European local language newsletters<\/li>\n<li>Preferential access to webinars and virtual and physical conferences<\/li>\n<\/ul>\n<p>If you are already a registered user or subscriber you can LOGIN below for ultimate access:<\/p>\n  <\/div>\n  <div class=\"mepr-login-form-wrap\">\n      \n<div class=\"mp_wrapper mp_login_form\">\n          <!-- mp-login-form-start -->     <form name=\"mepr_loginform\" id=\"mepr_loginform\" class=\"mepr-form\" action=\"https:\/\/www.commercialriskonline.com\/login\/\" method=\"post\">\n            <div class=\"mp-form-row mepr_username\">\n        <div class=\"mp-form-label\">\n                              <label for=\"user_login\">Username or E-mail<\/label>\n                  <\/div>\n        <input type=\"text\" name=\"log\" id=\"user_login\" value=\"\" \/>\n      <\/div>\n      <div class=\"mp-form-row mepr_password\">\n        <div class=\"mp-form-label\">\n          <label for=\"user_pass\">Password<\/label>\n                    <div class=\"mp-hide-pw\">\n            <input type=\"password\" name=\"pwd\" id=\"user_pass\" value=\"\" \/>\n            <button type=\"button\" class=\"button mp-hide-pw hide-if-no-js\" data-toggle=\"0\" aria-label=\"Show password\">\n              <span class=\"dashicons dashicons-visibility\" aria-hidden=\"true\"><\/span>\n            <\/button>\n          <\/div>\n        <\/div>\n      <\/div>\n            <div>\n        <label><input name=\"rememberme\" type=\"checkbox\" id=\"rememberme\" value=\"forever\" \/> Remember Me<\/label>\n      <\/div>\n      <div class=\"mp-spacer\">&nbsp;<\/div>\n      <div class=\"submit\">\n        <input type=\"submit\" name=\"wp-submit\" id=\"wp-submit\" class=\"button-primary mepr-share-button \" value=\"Log In\" \/>\n        <input type=\"hidden\" name=\"redirect_to\" value=\"\/wp-json\/wp\/v2\/posts\/86160\" \/>\n        <input type=\"hidden\" name=\"mepr_process_login_form\" value=\"true\" \/>\n        <input type=\"hidden\" name=\"mepr_is_login_page\" value=\"false\" \/>\n      <\/div>\n    <\/form>\n    <div class=\"mp-spacer\">&nbsp;<\/div>\n    <div class=\"mepr-login-actions\">\n      <a href=\"https:\/\/www.commercialriskonline.com\/login\/?action=forgot_password\">Forgot Password<\/a>\n    <\/div>\n    <!-- mp-login-form-end --> \n  <\/div>\n    <\/div>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"<p>The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called upon the EU to significantly strengthen provisions in free-trade agreements (FTAs) to strengthen intellectual property (IP) protection f&#8230; Want to read this article? Register for ultimate access to this article and ALL our premium content ULTIMATE ACCESS PROVIDES YOU &hellip;<\/p>\n","protected":false},"author":4,"featured_media":86161,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[359,360,354,1,517,160,141,191],"tags":[516,444,443,439],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"thumbnail":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-150x150.jpg",150,150,true],"medium":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-300x171.jpg",300,171,true],"medium_large":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"large":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"1536x1536":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"2048x2048":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"image-publication":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-390x223.jpg",390,223,true],"image-publication-large":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-476x272.jpg",476,272,true],"jannah-image-small":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-220x150.jpg",220,150,true],"jannah-image-large":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-390x220.jpg",390,220,true],"jannah-image-post":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981.jpg",700,400,false],"featured-2":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-530x340.jpg",530,340,true],"editors-pick":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-219x115.jpg",219,115,true],"archive-thumbnail":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-375x375.jpg",375,375,true],"mobile-thumbnail":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-375x300.jpg",375,300,true],"single-feature":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-700x400.jpg",700,400,true],"square-thumbnail-s":["https:\/\/www.commercialriskonline.com\/wp-content\/uploads\/2022\/01\/EU-pharma_shutterstock_549106981-100x100.jpg",100,100,true]},"uagb_author_info":{"display_name":"Ben Norris","author_link":"https:\/\/www.commercialriskonline.com\/author\/ben-norris\/"},"uagb_comment_info":0,"uagb_excerpt":"The European Federation of Pharmaceutical Industries and Associations (EFPIA) has called upon the EU to significantly strengthen provisions in free-trade agreements (FTAs) to strengthen intellectual property (IP) protection f... Want to read this article? Register for ultimate access to this article and ALL our premium content ULTIMATE ACCESS PROVIDES YOU &hellip;","_links":{"self":[{"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/posts\/86160"}],"collection":[{"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/comments?post=86160"}],"version-history":[{"count":1,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/posts\/86160\/revisions"}],"predecessor-version":[{"id":86162,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/posts\/86160\/revisions\/86162"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/media\/86161"}],"wp:attachment":[{"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/media?parent=86160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/categories?post=86160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.commercialriskonline.com\/wp-json\/wp\/v2\/tags?post=86160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}